|Bid||1.3150 x 334700|
|Ask||1.3500 x 1317400|
|Day's range||1.2800 - 1.3550|
|52-week range||1.0150 - 2.5200|
|Beta (5Y monthly)||1.30|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||25 Mar 1988|
|1y target est||N/A|
The makers of a nasal spray claim it's more than 99 per cent effective against the COVID-19 Delta variant sweeping the world, while the product has not had approval from Australian authorities.Melbourne-based biopharmaceutical group Starpharma on Tuesday published test results to show its Viraleze spray, already used in Europe and India, works well against the highly infectious Delta.
The last three months have been tough on Starpharma Holdings Limited ( ASX:SPL ) shareholders, who have seen the share...
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...